505 8th Avenue S.W.
Suit 420
Calgary, AB T2P 1G2
Canada
403-770-2469
https://marvelbiotechnology.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees:
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. J. Roderick Matheson | Executive Chairman & CEO | 150k | N/A | N/A |
Dr. Mark Williams M.B.A., Ph.D. | President, Chief Science Officer & Director | 150k | N/A | 1972 |
Mr. Harpreet Nijjar C.M.A., CPA | Chief Financial Officer | 82.5k | N/A | 1988 |
Ms. Jacqueline Groot | Corporate Secretary | N/A | N/A | N/A |
Marvel Biosciences Corp., a life sciences company, primarily focuses on the discovery and the development of synthetic derivative compound of a known proven drug. The company's lead compound MB-204, a novel fluorinated derivative of Istradefylline, which is a clinically approved adenosine A2a receptor antagonist used for the treatment of Parkinson's disease. It targets diseases, such as depression, Alzheimer's disease, and liver fibrosis due to non-alcoholic steatohepatitis. The company is headquartered in Calgary, Canada.
Marvel Biosciences Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.